- Home
- QNCX vs ADAP Comparison
QNCX vs ADAP Comparison
Compare QNCX & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- ADAP
- Stock Information
- Founded
- QNCX 2012
- ADAP 2008
- Country
- QNCX United States
- ADAP United Kingdom
- Employees
- QNCX N/A
- ADAP N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- QNCX Health Care
- ADAP Health Care
- Exchange
- QNCX Nasdaq
- ADAP Nasdaq
- Market Cap
- QNCX 44.0M
- ADAP 73.1M
- IPO Year
- QNCX 2019
- ADAP 2015
- Fundamental
- Price
- QNCX $1.03
- ADAP $0.30
- Analyst Decision
- QNCX Strong Buy
- ADAP Strong Buy
- Analyst Count
- QNCX 5
- ADAP 5
- Target Price
- QNCX $8.00
- ADAP $1.83
- AVG Volume (30 Days)
- QNCX 511.8K
- ADAP 775.4K
- Earning Date
- QNCX 05-16-2025
- ADAP 05-13-2025
- Dividend Yield
- QNCX N/A
- ADAP N/A
- EPS Growth
- QNCX N/A
- ADAP N/A
- EPS
- QNCX N/A
- ADAP N/A
- Revenue
- QNCX N/A
- ADAP $178,032,000.00
- Revenue This Year
- QNCX N/A
- ADAP N/A
- Revenue Next Year
- QNCX N/A
- ADAP $69.81
- P/E Ratio
- QNCX N/A
- ADAP N/A
- Revenue Growth
- QNCX N/A
- ADAP 195.34
- 52 Week Low
- QNCX $0.51
- ADAP $0.20
- 52 Week High
- QNCX $2.45
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- QNCX 38.67
- ADAP 53.92
- Support Level
- QNCX $0.98
- ADAP $0.30
- Resistance Level
- QNCX $1.16
- ADAP $0.32
- Average True Range (ATR)
- QNCX 0.09
- ADAP 0.02
- MACD
- QNCX 0.01
- ADAP 0.01
- Stochastic Oscillator
- QNCX 22.22
- ADAP 77.22
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.